Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bone Metastasis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Bone Metastasis - Pipeline Review, H1 2016', provides an overview of the Bone Metastasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Metastasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews pipeline therapeutics for Bone Metastasis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Bone Metastasis therapeutics and enlists all their major and minor projects - The report assesses Bone Metastasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Bone Metastasis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Bone Metastasis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Bone Metastasis Overview 10 Therapeutics Development 11 Pipeline Products for Bone Metastasis - Overview 11 Pipeline Products for Bone Metastasis - Comparative Analysis 12 Bone Metastasis - Therapeutics under Development by Companies 13 Bone Metastasis - Therapeutics under Investigation by Universities/Institutes 15 Bone Metastasis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Bone Metastasis - Products under Development by Companies 19 Bone Metastasis - Products under Investigation by Universities/Institutes 20 Bone Metastasis - Companies Involved in Therapeutics Development 21 Ablynx NV 21 Alethia Biotherapeutics Inc. 22 Amgen Inc. 23 Amura Holdings Limited 24 Bayer AG 25 Campus Technologies Freiburg GmbH 26 ChemoCentryx, Inc. 27 Deciphera Pharmaceuticals, LLC 28 Oncobiologics, Inc. 29 Oncodrone BV 30 Osteologix Holdings Plc 31 R-Pharm 32 Sigma-Tau S.p.A. 33 Taiho Pharmaceutical Co., Ltd. 34 Terpenoid Therapeutics, Inc. 35 Thar Pharmaceuticals, Inc. 36 Bone Metastasis - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 AB-25E9 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 ADM-01 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 ALX-0141 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AM-3701 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AMG-161 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 BKM-1644 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BKM-1740 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 CCX-354 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CCX-721 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 DCC-3014 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 denosumab - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 denosumab biosimilar - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 LG-1980 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 NBS-101 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 OCD-155 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 radium Ra 223 dichloride - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 roneparstat - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 RPH-203 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 RSF-102 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 RSF-103 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 TAS-115 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 TPH-9 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 vicrostatin - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 zoledronic acid - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Bone Metastasis - Recent Pipeline Updates 81 Bone Metastasis - Dormant Projects 100 Bone Metastasis - Discontinued Products 103 Bone Metastasis - Product Development Milestones 104 Featured News & Press Releases 104 Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan 104 Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride) 105 Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna 106 Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease 106 Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 107 Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 109 Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 109 Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 110 May 30, 2013: Algeta Announces First Sale Of Xofigo In US 111 Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 112 Appendix 113 Methodology 113 Coverage 113 Secondary Research 113 Primary Research 113 Expert Panel Validation 113 Contact Us 113 Disclaimer 114
List of Tables
Number of Products under Development for Bone Metastasis, H1 2016 11 Number of Products under Development for Bone Metastasis - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Bone Metastasis - Pipeline by Ablynx NV, H1 2016 21 Bone Metastasis - Pipeline by Alethia Biotherapeutics Inc., H1 2016 22 Bone Metastasis - Pipeline by Amgen Inc., H1 2016 23 Bone Metastasis - Pipeline by Amura Holdings Limited, H1 2016 24 Bone Metastasis - Pipeline by Bayer AG, H1 2016 25 Bone Metastasis - Pipeline by Campus Technologies Freiburg GmbH, H1 2016 26 Bone Metastasis - Pipeline by ChemoCentryx, Inc., H1 2016 27 Bone Metastasis - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 28 Bone Metastasis - Pipeline by Oncobiologics, Inc., H1 2016 29 Bone Metastasis - Pipeline by Oncodrone BV , H1 2016 30 Bone Metastasis - Pipeline by Osteologix Holdings Plc, H1 2016 31 Bone Metastasis - Pipeline by R-Pharm, H1 2016 32 Bone Metastasis - Pipeline by Sigma-Tau S.p.A., H1 2016 33 Bone Metastasis - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 34 Bone Metastasis - Pipeline by Terpenoid Therapeutics, Inc., H1 2016 35 Bone Metastasis - Pipeline by Thar Pharmaceuticals, Inc., H1 2016 36 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Bone Metastasis Therapeutics - Recent Pipeline Updates, H1 2016 81 Bone Metastasis - Dormant Projects, H1 2016 100 Bone Metastasis - Dormant Projects (Contd..1), H1 2016 101 Bone Metastasis - Dormant Projects (Contd..2), H1 2016 102 Bone Metastasis - Discontinued Products, H1 2016 103
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
